cover
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
japr.editor@gmail.com
Editorial Address
Plot No. 105/42, Opposite electricity sub station, Changorabhata, Raipur (Chhattisgarh), India 492001
Location
,
INDONESIA
Journal of Applied Pharmaceutical Research
Published by Creative Pharma Assent
ISSN : -     EISSN : 23480335     DOI : 10.18231
Core Subject : Health,
Journal of Applied Pharmaceutical Research (JOAPR) is an official publication of Creative Pharma Assent (CPA). It is an open access, peer review online international journal. JOAPR is primarily focused on multiple discipline of pharmaceutical sciences (Pharmaceutics, Pharmaceutical Technology, Biopharmaceutics, Cosmetic Technology, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Herbal drugs/ formulations, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest) which publish quarterly. JOAPR also includes evaluation of pharmaceutical excipients & their practical application to research & industry based efforts. The aim of the scientific journal, JOAPR is to present a wide area for the current researchers to share their noble works and ideas in terms of the research papers, review articles and short communications. JOAPR only publish the original research works with a definite innovation and novelty after thorough reviewing. The paper must have a suitable and proper scientific background.
Arjuna Subject : -
Articles 533 Documents
Optimization and evaluation of sirolimus nanodispersion drug-layered prednisolone tablets for the management of thrombocytopenia Pradeep Jena; Achal Mishra; Madhuri Baghel; Mayank Garhewal; Shekhar Verma
Journal of Applied Pharmaceutical Research Vol. 14 No. 4 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i4.2307

Abstract

Background: Thrombocytopenia is a hematological disorder characterized by a reduced platelet count, increasing the risk of bleeding and impairing hemostasis. The present study aimed to develop and optimize a fixed-dose combination tablet comprising a sirolimus nanodispersion layered onto a prednisolone core tablet using a Box–Behnken experimental design as a potential therapeutic strategy for thrombocytopenia. Methodology: Sirolimus nanodispersion drug-layered tablets were prepared and optimized using a three-factor, three-level Box–Behnken design. The optimized formulation was evaluated for critical quality attributes, including hardness and friability, and subsequently experimentally validated. Therapeutic efficacy was investigated in cyclophosphamide-induced thrombocytopenic Wistar rats by assessing platelet count, bleeding time, clotting time, and hematological parameters, including red blood cell count, hemoglobin, and hematocrit. Results and Discussion: The optimized formulation exhibited acceptable mechanical properties, with hardness ranging from 5.3 to 5.5 kg/cm² and friability below 1%, confirming the robustness of the optimization process. In vivo evaluation demonstrated a marked improvement in platelet recovery following treatment. The platelet count increased from 39.87 ± 8.82 × 10³/mm³ in the disease control group to 132.62 ± 21.76 × 10³/mm³ and 154.57 ± 7.40 × 10³/mm³ after once-daily and twice-daily administration, respectively. Furthermore, treatment significantly improved bleeding time, clotting time, and hematological parameters, indicating enhanced therapeutic efficacy. Conclusion: The optimized sirolimus nanodispersion drug-layered prednisolone tablet demonstrated favorable pharmaceutical characteristics and significant therapeutic efficacy in the cyclophosphamide-induced thrombocytopenia model. The developed fixed-dose combination represents a promising formulation strategy for improving the management of thrombocytopenia and warrants further preclinical and clinical investigation.
Creation and verification of an RP-UHPLC technique for abemaciclib and associated impurities in formulations and APIs using Box-Behnken design Kalpana Krishnaraju; Malarkodi Velraj
Journal of Applied Pharmaceutical Research Vol. 14 No. 4 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i4.2330

Abstract

Background: Strict impurity profiling is necessary to ensure the safety, effectiveness, and regulatory compliance of Abemaciclib (AbB), a selective CDK4/6 inhibitor frequently used in breast cancer treatment. However, a lack of thorough impurity separation, lengthy run times, and low sensitivity are common problems with current analytical techniques. Methodology: A novel reverse-phase ultra-high-performance liquid chromatography (RP-UHPLC) method was developed using a Quality by Design (QbD) framework. Critical method parameters, including mobile phase pH, flow rate, and column temperature, were optimized using Box-Behnken Design (BBD). Chromatographic separation was achieved on a C18 column using an isocratic mobile phase consisting of acetonitrile (40:60, v/v) and ammonium formate buffer (pH 2.7). The technique was validated in accordance with the ICH Q2(R1) requirements. Results and Discussion: The optimized method demonstrated exceptional linearity over the range of 0.02–150 μg/mL (R² > 0.999) with excellent precision (RSD < 2% for AbB and < 10% for related impurities) and showed acceptable accuracy, with mean recoveries ranging from 92.76% to 102.88% across AbB and its related impurities. The detection and quantification limits for AbB were 0.01 μg/mL and 0.02 μg/mL, respectively. Forced degradation studies that effectively distinguished degradation products in oxidative, acidic, and alkaline settings confirmed the method's stability-indicating nature. The 8-minute run time allowed for quick examination. The integration of BBD-based QbD significantly enhanced method robustness, resolution, and sensitivity compared to conventional chromatographic approaches, allowing simultaneous quantification of AbB and its related impurities. Conclusion: For routine quality control, stability investigations, and regulatory-compliant impurity profiling of Abemaciclib, the developed RP-UHPLC method is quick, sensitive, reliable, and appropriate.
Novel chemometric-driven greenness assessed spectroscopical method development and forced degradation study of sitagliptin phosphate in its bulk drug and ophthalmic formulation Debashis Mishra; Himansu Bhusan Samal; Diptimayee Jena; Kirtimaya Mishra
Journal of Applied Pharmaceutical Research Vol. 14 No. 4 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i4.2331

Abstract

Background: Sitagliptin phosphate (SIT), an antidiabetic drug, requires reliable analytical methods for routine quality control and stability assessment. UV-visible spectrophotometry offers a simple and economical approach; however, method robustness and stability-indicating capability must be ensured using systematic development strategies such as Quality by Design (QbD). The objective of this work is to develop and validate a rapid, simple, economical, accurate, and precise UV-visible spectrophotometric method with a stability-indicating capability for the analysis of SIT in bulk drug and ophthalmic formulation. Methodology: Method development was performed using a QbD approach in a quality control laboratory with a UV-visible spectrophotometer and 1 cm quartz cells. Various solvents (phosphate buffer, ethanol, acetonitrile, methanol, and water) were evaluated, with water selected due to superior solubility and spectral characteristics. SIT showed maximum absorbance at 265-267 nm. Forced degradation studies (acidic, basic, oxidative, thermal, and photolytic) were conducted. Validation was performed as per ICH Q2 (R1) guidelines. Results and Discussion: The developed method exhibited excellent linearity (R² ≥ 0.998), accuracy (99-101% recovery), and precision (%RSD ≤ 2%). Recovery ranged from 98.68% to 99.46%. The method was robust and successfully indicated stability under stress conditions. The application of QbD ensured systematic optimization and robustness. Water proved to be an ideal solvent, enhancing method simplicity and cost-effectiveness. The method effectively distinguished SIT from degradation products, confirming its stability-indicating nature. Conclusion: A validated, reliable, and economical UV-visible spectrophotometric method was successfully developed for SIT analysis, suitable for routine quality control and stability studies in bulk drug and ophthalmic formulations.
Solid self-microemulsifying drug delivery systems in modern pharmaceutics: design, characterization, and clinical applications P. R. Kaple; S. S. Agarwal
Journal of Applied Pharmaceutical Research Vol. 14 No. 4 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i4.2413

Abstract

Background: Approximately 40% of marketed medicines and 70% of pipeline products exhibit poor aqueous solubility, leading to inconsistent oral bioavailability and impaired efficacy. S-SMEDDS represent a revolutionary approach for converting liquids into stable solid dosage forms. Methodology: Methods employed to prepare S-SMEDDs include adsorption onto carriers, spray drying, hot-melt extrusion, and freeze-drying. Characterization includes assessing self-emulsifying behavior, dynamic light scattering, powder diffraction, and thermal analysis. Results and Discussion: Depending on the drug's characteristics, the formulation composition, and the study conditions, S-SMEDDS can increase bioavailability by two to ten times. However, for some extremely lipophilic BCS Class II and IV pharmaceuticals, significantly greater benefits (up to ~50-fold) have been documented. Several investigations have demonstrated that S-SMEDDS exhibit better physical and chemical stability than liquid systems under ICH Q1A(R2) accelerated storage conditions due to reduced lipid mobility and a lower risk of phase separation. Applications extend to the treatment of cardiovascular, oncological, and endocrine disorders with improved pharmacodynamic efficacy. The multiple absorption mechanisms in S-SMEDDS include improved solubilization, reduced precipitation, lymphotropic delivery, and inhibition of efflux pumps. They demonstrate higher chemical and physical stability, precise dosing, and better patient adherence when compared to traditional liquid counterparts. Conclusion: S-SMEDDS constitute an established pharmaceutical platform that overcomes the drawbacks associated with liquid lipid drug delivery systems. Their high effectiveness, manufacturability, and compatibility with novel technologies such as three-dimensional printing and artificial intelligence position them to be the foundation for precision oral drug delivery.
Structural innovation and therapeutic potential of oxazolidinone antibacterials Gopal Krishna Padhy; Jagadeesh Panda; Deepankar Rath
Journal of Applied Pharmaceutical Research Vol. 14 No. 5 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i5.1799

Abstract

Background: Oxazolidinones mark a major advance in antibacterial therapy, being the first new antibiotic class introduced into hospitals in over three decades. Their relevance is underscored by the global crisis of antimicrobial resistance (AMR), particularly against multidrug‑resistant Gram‑positive pathogens. Methodology: We conducted a systematic literature review using ScienceDirect and Google Scholar. We selected studies based on mechanistic insights, clinical efficacy, pharmacokinetics, safety, and resistance pathways. We emphasized FDA-approved agents (linezolid and tedizolid) and next-generation derivatives in clinical development. Results and Discussion: Linezolid and tedizolid inhibit bacterial protein synthesis by binding to the 23S rRNA of the ribosomal initiation complex. Tedizolid is more potent, has reduced mitochondrial toxicity, and inhibits monoamine oxidase less than linezolid. Resistance mechanisms include ribosomal mutations, methylation, efflux pumps, and enzymatic modifications. Structural innovations in tedizolid—such as its hydroxymethyl substituent—enhance ribosomal binding and mitigate cfr‑mediated resistance. The pipeline includes promising agents like sutezolid, delpazolid, contezolid, radezolid, and TBI‑223, many designed to overcome toxicity and resistance limitations. Comparative analysis highlights tedizolid’s improved therapeutic index and the convenience of once-daily dosing. Next‑generation oxazolidinones expand the scope to tuberculosis and other resistant infections, reflecting rational drug design informed by mechanistic understanding. Challenges remain in mitigating resistance and ensuring long‑term safety. Conclusion: Oxazolidinones remain vital in combating AMR. Continued innovation, structural refinement, and global stewardship are essential to sustain their efficacy and extend the clinical lifespan of this antibiotic class.
Recent insights into nanostructured lipid carriers for novel drug delivery systems Deepika; Yogita Tyagi; Anjali Bhatt; Robin Raj; Abhishek Kumar
Journal of Applied Pharmaceutical Research Vol. 14 No. 5 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i5.1932

Abstract

Background: Nanostructured lipid carriers (NLCs) are advanced lipid-based nanocarriers developed to overcome the limitations of conventional drug-delivery systems. Composed of a nanometric matrix of solid and liquid lipids, NLCs offer improved stability, safety, and drug-loading efficiency compared with other lipid, polymeric, or metallic nanoparticles. Their biocompatibility and non-toxicity make them attractive for pharmaceutical and biomedical applications. Methodology: This review systematically summarizes recent literature on NLC design, classification, structural characteristics, and preparation techniques. It discusses widely used formulation methods for lipid-based nanocarriers and strategies for surface modification to achieve targeted delivery and prolonged residence time. Results and Discussion: Nanostructured lipid carriers (NLCs) show high drug encapsulation efficiency, typically 70–95%, about 20–30% higher than conventional solid lipid nanoparticles (SLNs). Furthermore, NLCs enhance physicochemical stability, improve permeability, and increase the solubility of both hydrophilic and lipophilic drugs. Surface functionalization strategies enable controlled drug release and targeted delivery, thereby significantly improving therapeutic outcomes across multiple routes of administration. Because they can enhance bioavailability and protect encapsulated agents, NLCs are particularly well-suited for challenging delivery routes. Their versatility supports applications across a wide range of diseases, including infections, diabetes, cancer, neurodegenerative disorders, hypertension, and pain management. Conclusion: Overall, NLCs are a promising, versatile platform for safe and effective drug and gene delivery. Continued research and optimization may further expand their clinical potential across diverse therapeutic areas.
In vitro and in silico anthelmintic activity of the hydro-alcoholic extract of Stemona tuberosa roots C. Malsawmtluangi; H. Lalhlenmawia; Lalnun Hruaitluangi
Journal of Applied Pharmaceutical Research Vol. 14 No. 5 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i5.2057

Abstract

Background: Helminthiasis is a parasitic worm infection that can cause severe conditions in humans and animals. Current synthetic anthelmintic drugs are becoming less effective against helminths, prompting screening of more medicinal plants for anthelmintic properties. Stemona tuberosa has traditionally been used to treat various diseases, including helminthiasis. Therefore, we used in silico and in vitro approaches to investigate the traditional use of Stemona tuberosa roots. Methodology: We screened the phytohemical constituents of the plant's hydro-alcoholic extract using GC-MS. We carried out a computational study of anthelmintic activity using molecular docking and molecular dynamics simulations. We prepared standard drugs and plant extracts at different concentrations in Phosphate Buffer Solution (0.9%) and 1% DMSO. Intestinal and liver parasites obtained from Albino Wistar rats were used to assess in vitro anthelmintic activity.  The anthelmintic activity was then assessed from the paralysis and mortality time of the parasites. Results and Discussion: GC-MS analysis of the plant extract showed the presence of various phytochemicals. Molecular docking of quinic acid with the tubulin colchicine enzyme showed a good docking score (-10.698 kcal/mol), and Molecular dynamics simulation showed quinic acid's stability with the target protein. In vitro anthelmintic activity showed that the plant extract exhibited dose-dependent and significant anthelmintic effects on the parasites. Conclusions: The present study suggested that the plant extract exhibited anthelmintic activity, which may be attributed to its phytochemical constituents.
Design and development of transferrin conjugated quercetin-loaded nanostructured lipid carrier for cancer therapy Yogita Ale; Vikash Jakhmola; Shivani Kala; Malvika Kandpal
Journal of Applied Pharmaceutical Research Vol. 14 No. 5 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i5.2149

Abstract

Background: Glioblastoma multiforme is a highly invasive and aggressive brain cancer, with limited therapy options mostly due to the restrictive properties of the blood-brain barrier (BBB). The BBB limits the penetration of most therapeutic agents, leading to inadequate tumor specificity.  The tumor microenvironment exhibits overexpression of transferrin receptors on the BBB endothelial cells, facilitating receptor-mediated drug delivery. Methodology: This study involved the preparation of Quercetin (Que) loaded nanostructured lipid carriers (NLCs) employing the Box-Behnken design (BBD)of experimental methodology. The optimized formulation was subsequently conjugated with transferrin via EDC-mediated covalent conjugation. The attributes of the Que-NLCs and Tf-Que NLCs were validated using particle size, zeta potential, entrapment efficiency, drug loading, in vitro drug release, scanning electron microscopy (SEM), and transmission electron microscopy (TEM). NMR and coupling efficacy validated the conjugation of Tf on the surface of Que-NLCs. Results and Discussion: The in vitro investigation on the U251 cell line revealed that Que-NLCs showed potential anticancer activity with an IC₅₀ value of 20.8 μg/mL, and the optimized Tf-Que-NLCs (Tf/lipid ratio 20:80) exhibited an IC₅₀ value of 17.6 μg/mL. Tf-Que-NLCs showed higher cellular uptake (28.75 1.42%) and better permeability (1.5 times) than the standard drug and Que-NLCs in the BBB model hCMEC/D3 cell line, confirming receptor-mediated drug transport. The apoptosis investigation demonstrated planned cell death mostly via early and late apoptotic pathways, with no necrosis, suggesting a regulated cytotoxic mechanism. Conclusion: The results indicate that Tf-Que-NLCs constitute a promising nanocarrier formulation for the effective treatment of glioblastoma.
Musa paradisiaca (plantain/banana): an integrative review of nutritional, phytochemical, pharmacological, and green nanotechnology approaches for anemia prevention and management Rajeswar Das; Durgaprasad Kemisetti; Bolay Bhattacharya
Journal of Applied Pharmaceutical Research Vol. 14 No. 5 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i5.2200

Abstract

Background: Anemia remains a major global public health challenge, particularly in low- and middle-income countries, necessitating safe, affordable, and sustainable therapeutic approaches. M. paradisiaca (plantain/banana) has been widely recognized for its nutritional value and traditional medicinal uses and has recently gained attention for its potential role in anemia prevention through its bioactive constituents and emerging green nanotechnology applications. This review critically evaluates current evidence on M. paradisiaca's nutritional, phytochemical, pharmacological, and green nanotechnology-based potential for anemia prevention and management.  Methodology: Available evidence indicates that M. paradisiaca is a rich source of iron, vitamin C, folate, vitamin B6, copper, and diverse phytochemicals, including flavonoids, phenolic acids, tannins, and catechins. These constituents exhibit antioxidant, anti-inflammatory, antimicrobial, and metabolic regulatory activities that may support iron homeostasis, erythropoiesis, and protection against oxidative damage. Results and Discussion: Recent studies have also explored the green synthesis of iron oxide nanoparticles using M. paradisiaca extracts, demonstrating favorable physicochemical properties and potential for biomedical applications. However, evidence supporting their direct application in anemia management remains limited to preclinical investigations. Although the findings are encouraging, most evidence comes from in vitro and animal studies. Variability in plant parts, extraction methods, phytochemical composition, and nanoparticle synthesis protocols limits direct comparison among studies and clinical translation. Conclusion: M. paradisiaca is a promising nutritional resource with multifunctional biological activities that may help prevent and manage anemia. Nevertheless, standardized experimental studies and well-designed clinical trials are required to validate its therapeutic efficacy, particularly for green-synthesized iron oxide nanoparticles.
Phytochemical profiling and neuroprotective potential of Salix caprea extract against Alzheimer’s disease Swatantr Bahadur Singh; Mhaveer Singh; Pooja Saini
Journal of Applied Pharmaceutical Research Vol. 14 No. 5 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i5.2257

Abstract

Background: In the field of shrubs, the genus Salix is not sufficiently known. So, the author explored more about the plant and decided to study its neurological effects.  This research article focuses on the phytochemical analysis of the shrub Salix caprea and the assessment of its ethanolic extract on Swiss albino mice using different experimental models for preliminary anti-amnesic potential. Methodology: The twigs of Salix caprea were separated from a healthy, growing plant and transformed into powder. Then, phytochemical profiling was done as per the standard protocol. The shrub’s extract was prepared using Soxhlet equipment. The elevated plus maze method, Y-maze method, and passive avoidance test were used to assess the neurological effects. Scopolamine as an amnesia-inducing agent and donepezil as a standard drug were incorporated into the study protocol. Results and Discussion: Phytochemical investigation of Salix caprea revealed that it contains a remarkable amount of saponins, tannins, protein, and flavonoids. The pharmacological findings suggested that the plant extract at a dose of 200 mg/kg possesses therapeutic potential against Alzheimer's disease (AD). Statistical analysis was done to compare the significance of the activity. Conclusion: Salix caprea is well-known and investigated in the conventional medical system. Salix caprea’s ethanolic extract showed preliminary evidence of its efficacy as an anti-Alzheimer drug and memory enhancer. The observed anti-amnesic activity is hypothesized to involve interactions between the phytoconstituents of S. caprea and cholinergic receptors in the brain; however, this proposed mechanism requires further confirmation through receptor-binding and biochemical acetylcholinesterase assays.

Filter by Year

2013 2026


Filter By Issues
All Issue Vol. 14 No. 5 (2026) Vol. 14 No. 4 (2026) Vol. 14 No. 3 (2026) Vol. 13 No. 4 (2025) Vol. 13 No. 3 (2025) Vol. 13 No. 2 (2025) Vol. 13 No. 1 (2025) Vol. 12 No. 6 (2024) Vol. 12 No. 5 (2024) Vol. 12 No. 4 (2024) Vol. 12 No. 3 (2024) Vol. 12 No. 2 (2024) Vol. 12 No. 1 (2024) Vol. 11 No. 5 (2023) Vol. 11 No. 4 (2023) Vol. 11 No. 3 (2023) Vol. 11 No. 2 (2023) Vol. 11 No. 1 (2023) Vol. 10 No. 4 (2022) Vol. 10 No. 3 (2022) Vol. 10 No. 2 (2022) Vol. 10 No. 1 (2022) Vol. 9 No. 4 (2021) Vol. 9 No. 3 (2021) Vol. 9 No. 2 (2021) Vol. 9 No. 1 (2021) Vol. 8 No. 4 (2020) Vol. 8 No. 3 (2020) Vol. 8 No. 2 (2020) Vol. 8 No. 1 (2020) Vol. 7 No. 4 (2019) Vol. 7 No. 3 (2019) Vol 7 No 3 (2019) Vol. 7 No. 2 (2019) Vol 7 No 2 (2019) Vol. 7 No. 1 (2019) Vol 7 No 1 (2019) Vol. 6 No. 4 (2018) Vol 6 No 4 (2018) Vol. 6 No. 3 (2018) Vol 6 No 3 (2018) Vol. 6 No. 2 (2018) Vol 6 No 2 (2018) Vol. 6 No. 1 (2018) Vol 6 No 1 (2018) Vol 5 No 4 (2017) Vol. 5 No. 4 (2017) Vol 5 No 3 (2017) Vol. 5 No. 3 (2017) Vol. 5 No. 2 (2017) Vol 5 No 2 (2017) Vol. 5 No. 1 (2017) Vol 5 No 1 (2017) Vol 4 No 4 (2016) Vol. 4 No. 4 (2016) Vol. 4 No. 3 (2016) Vol 4 No 3 (2016) Vol. 4 No. 2 (2016) Vol 4 No 2 (2016) Vol. 4 No. 1 (2016) Vol 4 No 1 (2016) Vol. 3 No. 4 (2015) Vol 3 No 4 (2015) Vol 3 No 3 (2015) Vol. 3 No. 3 (2015) Vol. 3 No. 2 (2015) Vol 3 No 2 (2015) Vol 3 No 1 (2015) Vol. 3 No. 1 (2015) Vol 2 No 4 (2014) Vol. 2 No. 4 (2014) Vol. 2 No. 3 (2014) Vol 2 No 3 (2014) Vol 2 No 2 (2014) Vol. 2 No. 2 (2014) Vol. 2 No. 1 (2014) Vol 2 No 1 (2014) Vol. 1 No. 1 (2013) Vol 1 No 1 (2013) More Issue